Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2Adrenergic Receptor*

G protein-coupled receptors represent the largest class of drug discovery targets. Drugs that activate G protein-coupled receptors are classified as either agonists or partial agonists. To study the mechanism whereby these different classes of activating ligands modulate receptor function, we directly monitored ligand-induced conformational changes in the G protein-coupling domain of the β2 adrenergic receptor. Fluorescence lifetime analysis of a reporter fluorophore covalently attached to this domain revealed that, in the absence of ligands, this domain oscillates around a single detectable conformation. Binding to an antagonist does not change this conformation but does reduce the flexibility of the domain. However, when the β2 adrenergic receptor is bound to a full agonist, the G protein coupling domain exists in two distinct conformations. Moreover, the conformations induced by a full agonist can be distinguished from those induced by partial agonists. These results provide new insight into the structural consequence of antagonist binding and the basis of agonism and partial agonism.

[1]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[2]  P Ghanouni,et al.  Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  E. Freire,et al.  Can allosteric regulation be predicted from structure? , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  P. Ormos,et al.  Structural alterations for proton translocation in the M state of wild-type bacteriorhodopsin , 2000, Nature.

[5]  Richard Henderson,et al.  Molecular mechanism of vectorial proton translocation by bacteriorhodopsin , 2000, Nature.

[6]  P. Strange G-protein coupled receptors: conformations and states. , 1999, Biochemical pharmacology.

[7]  T. Kenakin Agonist-specific receptor conformations: Ligands create bias in already complex systems , 1997 .

[8]  S. Tuc̆ek,et al.  Is the R and R dichotomy real? , 1997, Trends in pharmacological sciences.

[9]  A M Krumins,et al.  The stability of the agonist beta2-adrenergic receptor-Gs complex: evidence for agonist-specific states. , 1997, Molecular pharmacology.

[10]  D. Selley,et al.  mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. , 1997, Molecular pharmacology.

[11]  H. Khorana,et al.  Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin , 1996, Science.

[12]  R. Graham,et al.  Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. , 1996, Molecular pharmacology.

[13]  P. Leff,et al.  The two-state model of receptor activation. , 1995, Trends in pharmacological sciences.

[14]  K. Fahmy,et al.  A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin. , 1994, The Journal of biological chemistry.

[15]  R. Aldrich,et al.  Shaker potassium channel gating. I: Transitions near the open state , 1994, The Journal of General Physiology.

[16]  K. Hideg,et al.  Photoactivated conformational changes in rhodopsin: a time-resolved spin label study. , 1993, Science.

[17]  R. Lefkowitz,et al.  Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. , 1993, Trends in pharmacological sciences.

[18]  R. Lefkowitz,et al.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.

[19]  P. Wolynes,et al.  The energy landscapes and motions of proteins. , 1991, Science.

[20]  M. Caron,et al.  Coupling of a mutated form of the human beta 2-adrenergic receptor to Gi and Gs. Requirement for multiple cytoplasmic domains in the coupling process. , 1991, The Journal of biological chemistry.

[21]  Joseph R. Lakowicz,et al.  A 10‐GHz frequency‐domain fluorometer , 1990 .

[22]  M. Tota,et al.  Partial agonist effects on the interaction between the atrial muscarinic receptor and the inhibitory guanine nucleotide-binding protein in a reconstituted system. , 1990, Molecular pharmacology.

[23]  B. Kobilka The role of cytosolic and membrane factors in processing of the human beta-2 adrenergic receptor following translocation and glycosylation in a cell-free system. , 1990, The Journal of biological chemistry.

[24]  E. Gratton,et al.  Protein Dynamics: Fluorescence Lifetime Distributions , 1989 .

[25]  M. Caron,et al.  Site-directed mutagenesis of the cytoplasmic domains of the human beta 2-adrenergic receptor. Localization of regions involved in G protein-receptor coupling. , 1988, The Journal of biological chemistry.